[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse COL4A3

Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix, basement membrane. Note=Colocalizes with COL4A4 and COL4A5 in GBM, tubular basement membrane (TBM) and synaptic basal lamina (BL).
Domain PF01413 C-terminal tandem repeated domain in type 4 procollagen
PF01391 Collagen triple helix repeat (20 copies)
Function

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.; FUNCTION: Tumstatin, a cleavage fragment corresponding to the collagen alpha 3(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity; these two anti-tumor properties may be regulated via RGD-independent ITGB3-mediated mechanisms.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0003013 circulatory system process
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007605 sensory perception of sound
GO:0008015 blood circulation
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0010466 negative regulation of peptidase activity
GO:0010950 positive regulation of endopeptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016525 negative regulation of angiogenesis
GO:0030198 extracellular matrix organization
GO:0030574 collagen catabolic process
GO:0032835 glomerulus development
GO:0032836 glomerular basement membrane development
GO:0032963 collagen metabolic process
GO:0034284 response to monosaccharide
GO:0043062 extracellular structure organization
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0045765 regulation of angiogenesis
GO:0045861 negative regulation of proteolysis
GO:0045862 positive regulation of proteolysis
GO:0048514 blood vessel morphogenesis
GO:0050954 sensory perception of mechanical stimulus
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072577 endothelial cell apoptotic process
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0005178 integrin binding
GO:0005201 extracellular matrix structural constituent
GO:0008191 metalloendopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0050839 cell adhesion molecule binding
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
GO:0005587 collagen type IV trimer
GO:0005604 basement membrane
GO:0005788 endoplasmic reticulum lumen
GO:0044420 extracellular matrix component
GO:0098642 network-forming collagen trimer
GO:0098644 complex of collagen trimers
GO:0098645 collagen network
GO:0098651 basement membrane collagen trimer
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04974 Protein digestion and absorption
Reactome R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-422475: Axon guidance
R-HSA-1650814: Collagen biosynthesis and modifying enzymes
R-HSA-8948216: Collagen chain trimerization
R-HSA-1474290: Collagen formation
R-HSA-1266738: Developmental Biology
R-HSA-1474244: Extracellular matrix organization
R-HSA-216083: Integrin cell surface interactions
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-419037: NCAM1 interactions
R-HSA-162582: Signal Transduction
R-HSA-186797: Signaling by PDGF
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between COL4A3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of COL4A3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of COL4A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5150.293
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8350.68
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1070.966
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1130.841
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2080.8
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3350.705
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3620.662
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2410.823
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0660.841
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of COL4A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.21111.20.194
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.211.910.30.33
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211742.917.625.30.161
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862533.3-8.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131153.89.144.70.0335
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.4018.40.0356
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.7022.70.134
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of COL4A3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of COL4A3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by COL4A3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of COL4A3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of COL4A3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between COL4A3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCOL4A3
Namecollagen, type IV, alpha 3 (Goodpasture antigen)
Aliases tumstatin; collagen IV, alpha-3 polypeptide; Goodpasture antigen; Collagen alpha-3(IV) chain
Chromosomal Location2q36-q37
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting COL4A3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.